Table: Taisho Pharmaceutical HD -2017/18 parent results
May 14 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2018 Mar 31, 2017 Mar 31, 2019 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Revenues 7.24 7.13
(+1.5 pct) (-0.8 pct)
Operating 5.68 5.47
(+3.8 pct) (-4.8 pct)
Recurring 5.61 5.41
(+3.7 pct) (-4.7 pct)
Net 5.53 6.86
(-19.3 pct) (+69.4 pct)
EPS 69.20 yen 85.76 yen
EPS Diluted 69.15 yen 85.70 yen
Ann Div 110.00 yen 110.00 yen 110.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 60.00 yen 60.00 yen 60.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10